PFMU
TCRX icon

Privium Fund Management (UK)’s TScan Therapeutics TCRX Stock Holding History

Privium Fund Management (UK)’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,103
Closed -$69.3K – 133
2024
Q2 		$69.3K Sell
12,103
-3,722
-24% -$29.3K 0.03% 155
2024
Q1 		$127K Hold
15,825
– – 0.06% 82
2023
Q4 		$92.3K Hold
15,825
– – 0.06% 72
2023
Q3 		$41.5K Hold
15,825
– – 0.03% 74
2023
Q2 		$40K Hold
15,825
– – 0.03% 69
2023
Q1 		$41K Hold
15,825
– – 0.03% 65
2022
Q4 		$24.5K Hold
15,825
– – 0.02% 54
2022
Q3 		$48K Buy
+15,825
New +$51.8K 0.06% 55

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Privium Fund Management (UK)'s TCRX Position: Q3 2024 in Review

Privium Fund Management (UK) sold out of TScan Therapeutics (TCRX) in Q3 2024, closing a stake of 12,103 shares — an estimated $69.3K sold.

Privium Fund Management (UK) first reported a position in TCRX in Q3 2022 and held it in 8 quarters. The position peaked at $127K in Q1 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q3 2024.

  • Privium Fund Management (UK) reported no remaining TScan Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Privium Fund Management (UK) sold 12,103 TScan Therapeutics shares in Q3 2024, an estimated $69.3K.
  • Privium Fund Management (UK) first reported a position in TScan Therapeutics in Q3 2022 and held it in 8 quarters.
  • Privium Fund Management (UK)'s TScan Therapeutics position peaked at $127K in Q1 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2024.

Based on Privium Fund Management (UK)'s 13F filing for Q3 2024, filed 5 Nov 2024.